EL7.AI
Mergers & AcquisitionsMedium•17 November 2026•
4 min read

Richter offers A$6.40 a share to acquire all of Mayne Pharma

Key Facts

1Mayne Pharma agreed to Gedeon Richter’s acquisition of 100% of its shares for A$6.40 a share in cash.
2The offer represents a 99.4% premium to the November 16, 2026 close.
33 major shareholders told the company they intended to vote for the deal, and together hold 22.14%.
4The company announced the sale of its international division to Evaris Pharma for $55.5 million.
5The scheme vote is expected in late January 2027 and implementation in March 2027, according to an indicative timetable.

Mayne Pharma has agreed to a deal under which Gedeon Richter will acquire all of the company’s shares for A$6.40 a share in cash, the company said in an announcement on November 17, 2026. The offer gives Mayne Pharma shareholders a fixed cash payment for each share instead of retaining their stakes in the company. The company said the agreement covers 100% of the shares. The board unanimously recommended that shareholders vote in favor of the deal, subject to the stated conditions. The deal is the focus of the announcement, while the reported 81% share gain in the initial account could not be confirmed through a reliable open source for this session.

The announcement set the premium at 99.4% to Mayne Pharma’s closing share price on November 16, 2026. The consideration also represents a 124% premium to the 30-day volume-weighted average price, 122% to the 90-day average and 145% to the 180-day average. These figures compare the offer price with specified earlier trading levels and do not, by themselves, establish that the premiums caused the share move on the day of the announcement. The 81% share gain in the relevant session could not be verified through reliable open coverage. Accordingly, the confirmed facts available here do not establish a share-performance figure for that day.

Mayne Pharma’s board said it unanimously recommended that shareholders vote in favor of the scheme. The recommendation remains conditional on no superior offer emerging and the independent expert continuing to regard the deal as being in shareholders’ best interests. This means the board’s position does not determine the vote or replace the expert’s assessment. The company said three major shareholders had told it they intended to support the deal unless a better offer emerged. Together, Funicular Funds, Bruce Mathieson and Trium Capital hold 22.14% of the ordinary shares.

According to the company, Funicular Funds holds about 9.82%, Bruce Mathieson 6.46% and Trium Capital 5.85%. It said these shareholders had indicated they intended to vote in favor of the deal in the absence of a superior proposal. Those stated commitments point to early support from major investors, but do not represent the vote of other shareholders. Approval of the scheme remains subject to a shareholder meeting and court approval, as well as the required regulatory approvals. Other conditions must also be met, including completion of the sale of the company’s international business.

Mayne Pharma said the deal is fully funded and is not subject to a financing condition. It remains subject to regulatory, shareholder and court approvals, as well as the independent expert’s conclusion and completion of the international business sale. The company announced on November 6 that it would sell the division to Evaris Pharma for $55.5 million, with customary completion adjustments related to working capital. This condition links the acquisition process to completion of the international asset sale. The available facts in the announcement did not specify a separate closing date for that transaction.

Mayne Pharma said the offer recognizes its U.S. women’s health and dermatology businesses, alongside its DistributeRx platform. This comes as the company moves to sell its international division to Evaris Pharma in a deal announced before the acquisition agreement. The sale announcement set base consideration at $55.5 million, subject to customary working-capital adjustments at completion. These steps do not mean the Richter deal has closed; the specified approvals and conditions remain outstanding. The board’s recommendation remains in effect, subject to no superior offer emerging and the independent expert continuing to find the deal in shareholders’ best interests.

The company expects the scheme vote to take place in late January 2027, with implementation in March 2027. The announcement described the timetable as indicative and subject to approvals and other conditions. The two dates therefore are not final dates for completing the deal. The move from agreement to implementation depends on securing regulatory, shareholder and court approvals, along with satisfying the remaining conditions. Completion of the international business sale also remains among the deal requirements.